This work presents the preparation of radiolabelled cis-dichlorodiammineplatinum (II), CDDP*, from its direct irradiation into a cadmium capsule, using the TRIGA MARK I IPR R-1 research reactor of the CDTN. The ability to detect CDDP* in Ehrlich tumour-bearing mice after administration via an intravenous route was evaluated. After 24 hours, blood and some organs were collected to determine the incorporated activity. The CDDP* showed a great chemical purity and high specific activity that resulted in an optimum in vivo detection. The CDDP* was taken up principally by liver, spleen and kidney. The CDDP* obtained from this condition was shown to be a good tool for biodistribution studies.
Radiolabelled cisplatin; biodistribution; TRIGA research reactor
